FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for predicting the effectiveness of neoadjuvant chemotherapy in triple negative breast cancer. After the second course of neoadjuvant chemotherapy, the level of tumor necrosis factor – TNFα is determined in the blood of patients suffering three negative breast cancer one day before the third course of neoadjuvant chemotherapy. If its level is reduced relative to its value one day before the first course of non-addictive chemotherapy by 50 % and more, the effectiveness of the conducted chemotherapy is predicted and the treatment is continued according to the used scheme. If the indicator is stabilized or increased, the development of resistance to the treatment is predicted and the chemotherapy regimen is changed.
EFFECT: method enables evaluating the effectiveness of neoadjuvant chemotherapy in the patients with thrice negative breast cancer ensured by the fact that in the second course of the neoadjuvant chemotherapy, day before 3rd course, TNFα level is determined in the patient's blood.
1 cl, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PREDICTING RESISTANCE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER | 2022 |
|
RU2802671C1 |
| METHOD OF PREDICTING EFFICIENCY OF NEOADJUVANT CHEMICAL THERAPY IN PATIENTS WITH RESECTABLE BASAL-LIKE TRIPLE-NEGATIVE BREAST CANCER | 2013 |
|
RU2538638C1 |
| METHOD OF TREATING PATIENTS WITH BRCA-ASSOCIATED TRIPLE-NEGATIVE LOCALLY ADVANCED BREAST CANCER | 2023 |
|
RU2814578C1 |
| METHOD FOR PREDICTION OF COMPLETE MORPHOLOGICAL REGRESSIONS IN PATIENTS SUFFERING TRIPLE-NEGATIVE RESECTABLE BREAST CANCER | 2014 |
|
RU2560707C1 |
| ONCOLYTIC TREATMENT METHOD FOR BREAST CANCER | 2018 |
|
RU2695136C1 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPING DISTANT METASTASES IN PATIENTS WITH OPERABLE FORMS OF BREAST CANCER WITH METASTASES IN REGIONAL LYMPH NODES | 2020 |
|
RU2733697C1 |
| METHOD OF PREDICTING ACHIEVEMENT OF COMPLETE MORPHOLOGICAL REGRESSIONS IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER, WHO OBTAINED CHEMOTHERAPY COURSES IN CAX REGIMEN | 2014 |
|
RU2563180C1 |
| METHOD FOR ASSESSMENT OF TUMOUR SENSITIVITY TO CHEMOTHERAPY OF PATIENTS WITH LOCALLY ADVANCED BREAST CANCER | 2015 |
|
RU2616532C1 |
| METHOD FOR PREDICTION OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH THREE-TIMES NEGATIVE MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2623118C1 |
| METHOD FOR PREDICTION OF DEGREE OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH LUMINAL MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2632112C1 |
